Aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
View Patent ↗The present invention is directed to novel substituted aminopiperidines which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
1. A compound of the formula I:
or a pharmaceutically acceptable salt thereof; wherein
each n is independently 0, 1, 2 or 3;
Ar is phenyl unsubstituted or substituted with one to five R 3 substituents;
each R 3 is independently selected from the group consisting of
halogen,
cyano,
hydroxy,
C 1-6 alkyl, unsubstituted or substituted with one to five halogens, and
C 1-6 alkoxy, unsubstituted or substituted with one to five halogens;
R 1 is heteroaryl unsubstituted or substituted with one to four R 2 substituents, wherein the heteroaryl is selected from the group consisting of
each R 2 is independently selected from the group consisting of
hydroxy,
halogen,
cyano,
nitro,
C 1-10 alkoxy, wherein alkoxy is unsubstituted or substituted with one to five substituents independently selected from halogen or hydroxy,
C 1-10 alkyl, wherein alkyl is unsubstituted or substituted with one to five substituents independently selected from halogen or hydroxy,
C 2-10 alkenyl, wherein alkenyl is unsubstituted or substituted with one to five substituents independently selected from halogen or hydroxy,
(CH 2 ) n -aryl, wherein aryl is unsubstituted or substituted with one to five substituents independently selected hydroxy, halogen, cyano, nitro, CO 2 H, C 1-6 alkyloxycarbonyl, C 1-6 alkyl, and C 1-6 alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens,
(CH 2 ) n -heteroaryl, wherein heteroaryl is unsubstituted or substituted with one to three substituents independently selected from hydroxy, halogen, cyano, nitro, CO 2 H, C 1-6 alkyloxycarbonyl, C 1-6 alkyl, and C 1-6 alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens,
(CH 2 ) n -heterocyclyl, wherein heterocyclyl is unsubstituted or substituted with one to three substituents independently selected from oxo, hydroxy, halogen, cyano, nitro, CO 2 H, C 1-6 alkyloxycarbonyl, C 1-6 alkyl, and C 1-6 alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens,
(CH 2 ) n —C 3-6 cycloalkyl, wherein cycloalkyl is unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy, cyano, nitro, CO 2 H, C 1-6 alkyloxycarbonyl, C 1-6 alkyl, and C 1-6 alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens,
(CH 2 ) n —COOH,
(CH 2 ) n —COOC 1-6 alkyl,
(CH 2 ) n —NR 4 R 5 ,
(CH 2 ) n —CONR 4 R 5 ,
(CH 2 ) n —OCONR 4 R 5 ,
(CH 2 ) n —SO 2 NR 4 R 5 ,
(CH 2 ) n —SO 2 R 6 ,
(CH 2 ) n —NR 7 SO 2 R 6 ,
(CH 2 ) n —NR 7 CONR 4 R 5 ,
(CH 2 ) n —NR 7 COR 7 , and
(CH 2 ) n —NR 7 CO 2 R 6 ;
wherein any individual methylene (CH 2 ) carbon atom in (CH 2 ) n is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, C 1-4 and C 1-4 alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens;
R 4 and R 5 are each independently selected from the group consisting of
hydrogen,
(CH 2 ) n -phenyl,
(CH 2 ) n —C 3-6 cycloalkyl, and
C 1-6 alkyl;
wherein alkyl is unsubstituted or substituted with one to five substituents independently selected from halogen and hydroxy and wherein phenyl and cycloalkyl are unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C 1-6 alkyl, and C 1-6 alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens;
or R 4 and R 5 substituents together with the nitrogen atom to which they are attached form a heterocyclic ring selected from azetidine, pyrrolidine, piperidine, piperazine, and morpholine wherein said heterocyclic ring is unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy, C 1-6 alkyl, and C 1-6 alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens;
each R 6 is independently C 1-6 alkyl, wherein alkyl is unsubstituted or substituted with one to five substituents independently selected from halogen and hydroxyl; and
R 7 is hydrogen or R 6 .
2. The compound of claim 1 wherein R 3 is selected from the group consisting of fluorine, chlorine, bromine, methyl, trifluoromethyl, and trifluoromethoxy.
3. The compound of claim 1 wherein said heteroaryl group R 1 is selected from the group consisting of:
4. The compound of claim 3 wherein said heteroaryl group R 1 is selected from the group consisting of:
5. The compound of claim 4 wherein said heteroaryl group R 1 is selected from the group consisting of:
6. The compound of claim 1 wherein R 2 is selected from the group consisting of
halogen,
cyano,
nitro,
C 1-10 alkoxy, wherein alkoxy is unsubstituted or substituted with one to five substituents independently selected from halogen or hydroxy,
C 1-10 alkyl, wherein alkyl is unsubstituted or substituted with one to five substituents independently selected from halogen or hydroxy,
aryl, wherein aryl is unsubstituted or substituted with one to five substituents independently selected hydroxy, halogen, cyano, nitro, CO 2 H, C 1-6 alkyloxycarbonyl, C 1-6 alkyl, and C 1-6 alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens,
heteroaryl, wherein heteroaryl is unsubstituted or substituted with one to three substituents independently selected from hydroxy, halogen, cyano, nitro, CO 2 H, C 1-6 alkyloxycarbonyl, C 1-6 alkyl, and C 1-6 alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens, and
C 3-6 cycloalkyl, wherein cycloalkyl is unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy, cyano, nitro, COOH, C 1-6 alkoxycarbonyl, C 1-6 alkyl, and C 1-6 alkoxy, wherein said alkyl and alkoxy are unsubstituted or substituted with one to five halogens.
7. The compound of claim 6 wherein R 2 is selected from the group consisting of:
fluoro,
chloro,
cyano,
nitro,
C 1-4 alkyl,
trifluoromethyl,
methoxy,
4-fluorophenyl,
cyclohexyl, and
thienyl.
8. The compound of claim 1 of structural formulae Ia and Ib having the indicated stereochemical configuration at the two stereogenic piperidine carbon atoms marked with an *:
9. The compound of claim 8 of structural formula Ia having the indicated absolute stereochemical configuration at the two stereogenic piperidine carbon atoms marked with an *:
10. The compound of claim 9 wherein Ar is phenyl unsubstituted or substituted with one to three R 3 substituents independently selected from fluorine and trifluoromethyl; and
R 1 is a heteroaryl group selected from the group consisting of:
wherein said heteroaryl group is unsubstituted or substituted with one to two R 2 substituents independently selected from the group consisting of:
fluoro,
chloro,
cyano,
nitro,
C 1-4 alkyl,
trifluoromethyl,
methoxy,
4-fluorophenyl,
cyclohexyl, and
thienyl.
11. The compound of claim 10 wherein said heteroaryl group R 1 is selected from the group consisting of:
12. The compound of claim 10 which is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
13. A pharmaceutical composition which comprises a compound of claim 1 and a pharmaceutically acceptable carrier.
14. The pharmaceutical composition of claim 13 additionally comprising metformin.
15. A method for treating non-insulin dependent (Type 2) diabetes in a mammal in need thereof which comprises the administration to the mammal of a therapeutically effective amount of a compounds of claim 1 .